Combinations of muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US-2025339413-A1 · Nov 6, 2025 · US
This page is not indexed by search engines while we improve data quality.
Bruce Mark patents
Bruce Mark is listed as an inventor on 37 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Bruce Mark |
| Total patents | 37 |
| First publication | Mar 12, 2015 |
| Latest publication | Nov 6, 2025 |
Notable patents
Publications ranked by popularity score, then publication date.
Combinations of a muscarinic receptor antagonist and a β-2 adrenoreceptor agonist
US-12396986-B2 · Aug 26, 2025 · US
Modified helicases
US-12258591-B2 · Mar 25, 2025 · US
Modified enzymes
US-11965183-B2 · Apr 23, 2024 · US
Mutant pore
US-11939359-B2 · Mar 26, 2024 · US
Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US-2024041846-A1 · Feb 8, 2024 · US
Mutant lysenin pores
US-11845780-B2 · Dec 19, 2023 · US
Method of improving the movement of a target polynucleotide with respect to a transmembrane pore
US-11739377-B2 · Aug 29, 2023 · US
Modified helicases
US-2023212535-A1 · Jul 6, 2023 · US
Modified enzymes
US-2022135956-A1 · May 5, 2022 · US
Recent patents
Latest publications not already listed above.
Mutant pore
US-2022064230-A1 · Mar 3, 2022 · US
Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US-2022047565-A1 · Feb 17, 2022 · US
Modified enzymes
US-11180741-B2 · Nov 23, 2021 · US
Mutant lysenin pores
US-2021324020-A1 · Oct 21, 2021 · US
Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
US-11116721-B2 · Sep 14, 2021 · US
Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US-11090294-B2 · Aug 17, 2021 · US
Method of improving the movement of a target polynucleotide with respect to a transmembrane pore
US-2021139972-A1 · May 13, 2021 · US
Modified helicases
US-2021123032-A1 · Apr 29, 2021 · US
Modified helicases
US-2021009971-A1 · Jan 14, 2021 · US
Mutant lysenin pores
US-10882889-B2 · Jan 5, 2021 · US
Modified helicases
US-10808231-B2 · Oct 20, 2020 · US
Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US-2020171009-A1 · Jun 4, 2020 · US
Method for controlling the movement of a polynucleotide through a transmembrane pore
US-10392658-B2 · Aug 27, 2019 · US
Enzyme construct
US-2018230526-A1 · Aug 16, 2018 · US
Mutant lysenin pores
US-2018208632-A1 · Jul 26, 2018 · US
Modified enzymes
US-2018179500-A1 · Jun 28, 2018 · US
Modified helicases
US-2018037874-A9 · Feb 8, 2018 · US
Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US-2018008582-A1 · Jan 11, 2018 · US
Enzyme construct
US-9797009-B2 · Oct 24, 2017 · US
Mutant lysenin pores
US-9777049-B2 · Oct 3, 2017 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Oxford Nanopore Tech Ltd | 24 |
| Glaxo Group Ltd | 10 |
| Oxford Nanopore Tech Plc | 6 |
| Baker Darrell | 1 |
| Bruce Mark | 1 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| C12Q1/6869 | 24 |
| C12N9/14 | 15 |
| C12Q2565/631 | 13 |
| C12Y306/04012 | 12 |
| A61K9/0075 | 10 |